Pipeline

Our DARPin platform has vast applicability across a range of diseases. Explore our pipeline:

Oncology
Radio-DARPin Therapy
Virology
Candidate
Research
Preclinical
Phase 1
Phase 2
Phase 3
Rights
MP0317 / FAP x CD40: Advanced Solid Tumors
Phase 1
MP0533 / CD33 x CD123 x CD70 x CD3: r/r AML and AML/MDS
Phase 1
Switch-DARPin / cKIT x CD16a x CD47
Research
Co-development*
Radio-DARPin Therapy: DLL3
Research
In-house programs
Radio-DARPin Therapy: Solid Tumors
Preclinical
2 partnered programs
Radio-DARPin Therapy: Solid Tumors
Preclinical
Virology
Research

*The co-development agreement with Orano Med includes up to 3 potential oncology targets including DLL3.